Menu

Area Soci

Startup Name
ALTHEIA SCIENCE

Website (URL)
altheiascience.com

Country
Italy

Italy province
Milano

City
Milano

One line pitch
Technology: Cell&Gene Therapy Disease focus: Type I Diabetes and Multiple Sclerosis Clinical status: Pre-clinical

Short Description
Altheia Science develops a gene therapy-based approach in Type I diabetes and multiple sclerosis that aims at reverting the root cause of the disease, by ex vivo lentiviral vector-transducing autologous hematopoietic stem and progenitor cells (HSPC) to reconstitute PD-L1 expression. Re-inoculation of modified HPSC should entail the establishment of a correct balance in controlling immune responses, by promoting a tolerogenic effect triggering the PD-1/PD-L1 axis with the result to exhaust auto-reactive T lymphocytes effector capabilities, thus preventing auto-immune reactions against self-antigens. The approach has the potential to be transformative in the management of autoimmune diseases.

Funded
yes

Type of investors who funded this startup

  • Venture Capital

Incubated or Accelerated
no

Industry
Human health activities

Bitnami